NEW YORK (GenomeWeb) – Luminex said today that the US Food and Drug Administration has given 510(k) clearance for the firm's Aries C. difficile assay — a moderate complexity, sample-to-answer test for rapid detection of Clostridium difficile, which has become a common microbial cause of healthcare-associated infections in US hospitals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.